



href="http://www.uniprot.org/citations/9839948" target="\_blank">9839948</a>). The first step of fatty acid beta-oxidation consists in the removal of one hydrogen from C-2 and C-3 of the straight-chain fatty acyl-CoA thioester, resulting in the formation of trans-2-enoyl- CoA (PubMed:<a href="http://www.uniprot.org/citations/18227065" target="\_blank">18227065</a>, PubMed:<a href="http://www.uniprot.org/citations/7668252" target="\_blank">7668252</a>, PubMed:<a href="http://www.uniprot.org/citations/9461620" target="\_blank">9461620</a>, PubMed:<a href="http://www.uniprot.org/citations/9839948" target="\_blank">9839948</a>). Among the different mitochondrial acyl-CoA dehydrogenases, very long- chain specific acyl-CoA dehydrogenase acts specifically on acyl-CoAs with saturated 12 to 24 carbons long primary chains (PubMed:<a href="http://www.uniprot.org/citations/21237683" target="\_blank">21237683</a>, PubMed:<a href="http://www.uniprot.org/citations/9839948" target="\_blank">9839948</a>).

#### Cellular Location

Mitochondrion inner membrane; Peripheral membrane protein

#### Tissue Location

Predominantly expressed in heart and skeletal muscle (at protein level). Also detected in kidney and liver (at protein level).

#### VLCAD Antibody (C-Term, near) - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

#### VLCAD Antibody (C-Term, near) - Images



AF3126a (1 µg/ml) staining of Human Heart lysate (35 µg protein in RIPA buffer). Primary incubation was 1 hour. Detected by chemiluminescence.

#### VLCAD Antibody (C-Term, near) - Background

This antibody is expected to recognize both reported isoforms (NP\_000009.1; NP\_001029031.1).

#### **VLCAD Antibody (C-Term, near) - References**

Genetic

basis for correction of very-long-chain acyl-coenzyme A dehydrogenase deficiency by bezafibrate in patient fibroblasts: toward a genotype-based therapy. Gobin-Limballe S, Djouadi F, Aubey F, Olpin S, Andresen BS, Yamaguchi S, Mandel H, Fukao T, Ruiten JP, Wanders RJ, McAndrew R, Kim JJ, Bastin J. Am J Hum Genet. 2007 Dec;81(6):1133-43. PMID: 17999356